Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer
The role of biomarkers in guiding treatment for early-stage breast cancerПодробнее
Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast CancerПодробнее
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast CancerПодробнее
Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast CancerПодробнее
Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast CancerПодробнее
Dr Sara M. Tolaney: Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast CancerПодробнее
Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast CancerПодробнее
Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast CancerПодробнее
Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast CancerПодробнее
Neoadjuvant Approaches for Early-Stage HER2+ Breast CancersПодробнее
Current standards for HER2+ early stage breast cancerПодробнее
Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast CancerПодробнее
Dr. Tolaney on the ATEMPT Trial for HER2+ Breast CancerПодробнее
Evaluating the Role of Neoadjuvant Endocrine Therapy in Breast CancerПодробнее
Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast CancerПодробнее
Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast CancerПодробнее
Dr. Tolaney on the Evolution of Treatment in HER2+ Breast CancerПодробнее
TILs as a prognostic biomarker for treatment de-escalation in HER2-positive breast cancerПодробнее
Dr. Tolaney Discusses the Role of Chemotherapy in HER2+ Breast CancerПодробнее
